logo

ACAD

Acadia Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)

ACAD fundamentals

Acadia Pharmaceuticals (ACAD) expects to report earnings on Feb 25, 2026, with estimated revenue of 292.92M (YoY +12.84%), and EPS at 0.1334 (YoY -84.49%).
Revenue estimate / YoY
292.92M
+12.84%
EPS estimate / YoY
0.1334
-84.49%
Report date
Feb 25, 2026
Earnings Call
4:30 PM on Feb 25, 2026
Meeting link.
EPS
Revenue

Revenue & Expenses

ACAD has released its 2025 Q3 earnings report, with revenue of 278.63M, reflecting a YoY change of 11.27%, and net profit of 71.78M, showing a YoY change of 119.07%. The Sankey diagram below clearly presents ACAD's revenue sources and cost distribution.

Key Indicators

Acadia Pharmaceuticals (ACAD) key financial stats and ratios, covering profitability, financial health, and leverage.
Acadia Pharmaceuticals (ACAD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Acadia Pharmaceuticals (ACAD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Acadia Pharmaceuticals (ACAD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Acadia Pharmaceuticals (ACAD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Acadia Pharmaceuticals (ACAD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield